| Dr James John Mcelroy Jr, DC | |
|
233 W Absecon Blvd, Absecon, NJ 08201-2403 | |
| (609) 748-0063 | |
| Not Available |
| Full Name | Dr James John Mcelroy Jr |
|---|---|
| Gender | Male |
| Speciality | Chiropractic |
| Experience | 27 Years |
| Location | 233 W Absecon Blvd, Absecon, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831144195 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 111N00000X | Chiropractor | MC00526300 (New Jersey) | Primary |
| Provider Name | Mcelroy Chiropractic Center Llc |
|---|---|
| Provider Type | Part B Supplier - Clinic/group Practice |
| Provider Identifiers | NPI Number: 1508809237 PECOS PAC ID: 8921151507 Enrollment ID: O20090729000553 |
News Archive
Ten times more sensitive than current techniques, the technique allows, from a blood serum sample, to simultaneously detect different biomarkers related to cancer.
EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.
Gene therapy could offer a new, long-lasting way to treat Parkinson's disease, research results announced Tuesday 15 July at FENS 2008 suggest. Dr Deniz Kirik of the University of Lund in Sweden has been using viruses to insert a new combination of genes into animals' brains, where they help produce the dopamine that is lacking in Parkinson's disease. The results suggest the treatment is very effective in animal models for several months, possibly years.
A novel radiopharmaceutical probe developed at Massachusetts General Hospital has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism - conditions caused when important blood vessels are blocked by a clot that has traveled from another part of the body.
MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr James John Mcelroy Jr, DC 1109 Zion Rd, Northfield, NJ 08225-2213 Ph: (609) 485-0127 | Dr James John Mcelroy Jr, DC 233 W Absecon Blvd, Absecon, NJ 08201-2403 Ph: (609) 748-0063 |
News Archive
Ten times more sensitive than current techniques, the technique allows, from a blood serum sample, to simultaneously detect different biomarkers related to cancer.
EDAP TMS SA, the global leader in therapeutic ultrasound, today announced its strategy for the ongoing U.S. ENLIGHT Ablatherm-HIFU clinical trial. Following the FDA Gastroenterology and Urology Devices Panel in December 2009 and the Company's January 2010 meeting with the FDA concerning its recommendations for the trial protocol, the Company has thoroughly evaluated all options aiming at an IDE submission in a feasible timeframe and with acceptable economics.
Gene therapy could offer a new, long-lasting way to treat Parkinson's disease, research results announced Tuesday 15 July at FENS 2008 suggest. Dr Deniz Kirik of the University of Lund in Sweden has been using viruses to insert a new combination of genes into animals' brains, where they help produce the dopamine that is lacking in Parkinson's disease. The results suggest the treatment is very effective in animal models for several months, possibly years.
A novel radiopharmaceutical probe developed at Massachusetts General Hospital has the potential of providing physicians with information that could save the lives of patients with ischemic stroke or pulmonary embolism - conditions caused when important blood vessels are blocked by a clot that has traveled from another part of the body.
MannKind Corporation today announced that it has submitted, and the U.S. Food and Drug Administration has accepted, MannKind's resubmission of its New Drug Application for AFREZZA™ (insulin human [rDNA origin]) and classified it as a Class 2 resubmission. With the Class 2 designation, the FDA set a corresponding Prescription Drug User Fee Act action date of December 29, 2010.
› Verified 4 days ago
Dr. Colin Wills, DC Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 624 N Shore Rd, Absecon, NJ 08201 Phone: 609-677-5766 Fax: 609-677-5767 | |
Mcelroy Chiropractic Center Llc Chiropractor Medicare: Medicare Enrolled Practice Location: 233 W Absecon Blvd, Absecon, NJ 08201 Phone: 609-748-0063 Fax: 609-748-3063 | |
Dr. Lenise Racquel Graddy, D.C. Chiropractor Medicare: Not Enrolled in Medicare Practice Location: 403 Reed Road, Absecon, NJ 08201 Phone: 609-992-6926 |